Tiziana presents BANYAN trial poster on intranasal foralumab in ALS at conference

Tiziana Life Sciences announced on August 24, 2026 that a poster on its Phase 2a "BANYAN" trial of intranasal foralumab was presented at ALS Nexus 2026 in Orlando, Florida. The poster, titled "Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial," was presented by Dr. Pinar Uysal from 4:30 to 6:30 p.m. ET during a scientific poster session at the Hyatt Regency Grand Cypress Resort.¹

The presentation covered the BANYAN trial's place within the Healey ALS MyMatch program at Mass General Brigham's Sean M. Healey & AMG Center for ALS, along with preclinical data supporting foralumab in ALS, study design, and the ALS MyMatch Common Screening Protocol.¹

The trial itself is structured as a randomized, placebo-controlled study with a 3:1 ratio of foralumab to placebo, and receives financial support from multiple sources. It has backing from a grant from the ALS Association, with additional partial funding from the Martha Olson-Fernandez Foundation and the ALS Bridge Foundation, and aims to evaluate safety along with biomarkers tied to immune modulation and neuroinflammation, including microglial activation measured through PET imaging, as well as early indications of clinical benefit.¹ The study will run across sites in the Network of Excellence for ALS and will use the Healey ALS MyMatch infrastructure for trial operations.¹

As of the announcement, the trial remains in its operational startup phase, with enrollment timing and site locations to be detailed in a future press release.¹

The release also outlined biological rationale, noting that people with ALS often show reduced numbers and impaired function of regulatory T cells, which correlates with faster disease progression, since these cells normally help control inflammation and support tissue and immune homeostasis; when their activity is insufficient, unchecked neuroinflammation and microglial activation can worsen motor neuron damage.¹